Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Inflammation-Induced CNS Glutamate Changes in Depression
NCT03004443 · Emory University · PHASE4 · terminated · last registry update 2023-10-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was suspended in March 2020 due to the COVID-19 pandemic and ultimately was terminated as it is not safe to test a potent anti-inflammatory drug with ongoing surges of COVID-19.” | – | Registry record, Emory University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-23Results posted on the registry: UCB BIOSCIENCES GmbH, Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP) (NCT01550003)
- 2024-09-26Phase 3 first posted: JAROSLAW KIERKUS, Infliximab (NCT06614387)
- 2024-09-19Results posted on the registry: UCB Biopharma SRL, Pharmacokinetics of certolizumab pegol (NCT04163016)
- 2024-08-29Results posted on the registry: Washington University School of Medicine, Infliximab (NCT05340764)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-07-10Results posted on the registry: University of Illinois Chicago, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg) + Certolizumab pegol (CDP870, tradename Cimzia) (NCT02451748)
- 2024-06-04Phase 3 first posted: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), anti-tumour necrosis factor α antibodies (NCT06441526)
- 2024-03-26Results posted on the registry: ECOG-ACRIN Cancer Research Group, Infliximab + Intravenous Immunoglobulin Therapy (NCT04438382)
- 2024-02-23Phase 3 first posted: CMC Ambroise Paré, CT-P13 (NCT06274294)
- 2023-12-12Results posted on the registry: Janssen Research & Development, LLC, Guselkumab Dose 1 + Guselkumab Dose 2 (NCT03662542)
- 2023-11-13Results posted on the registry: UCB Biopharma SRL, Certolizumab pegol (NCT04740814)
- 2023-10-23Results posted on the registry: Celltrion, CT-P13 SC (Infliximab) (NCT03945019)
- 2023-09-29Phase 3 first posted: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Infliximab subcutaneous + Immunosuppressive Agents (NCT06059989)
- 2023-09-28Results posted on the registry: Celltrion, CT-P13 SC (Infliximab) (NCT04205643)
- 2023-07-27Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Certolizumab pegol (NCT03215277)
- 2023-07-17Phase 3 first posted: Odense University Hospital, Infliximab + Methylprednisolone (NCT05947669)
- 2023-07-05Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Certolizumab (CIMZIA® ; TNF-α antagonist) + Placebo (NaCl 0.9 % solution) (NCT05930613)
- 2023-05-03Phase 3 first posted: Alvotech Swiss AG, AVT05 (proposed biosimilar to golimumab) + Simponi (Golimumab) (NCT05842213)
- 2023-04-21Results posted on the registry: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2023-04-07Also stopped (terminated): Wenjie Zheng, Golimumab (GOL) (NCT04218565)
- 2023-02-08Results posted on the registry: Novartis Pharmaceuticals, Ruxolitinib (RUX) + Best Available Therapy (BAT) (NCT02913261)
- 2023-01-25Results posted on the registry: Nichi-Iko Pharmaceutical Co., Ltd., NI-071 + Remicade (NCT02990806)
- 2023-01-20Results posted on the registry: Johnson & Johnson Private Limited, Golimumab (NCT03733925)
- 2023-01-19Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, STOP arm (NCT05689879)
- 2023-01-03Phase 3 first posted: University of Pennsylvania, Guselkumab + Golimumab (NCT05669833)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision